ARTICLE | Clinical News
Vestra reboxetine selective norepinephrine reuptake inhibitor regulatory update
May 21, 2001 7:00 AM UTC
PHA received a non-approvable letter from the FDA for Vestra to treat depression. The original Vestra NDA was submitted in 1998, and contained data from studies primarily outside the U.S. The FDA requ...